Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

The anti-inflammatory effects of sulforaphane are not mediated by the Nrf2 pathway

Andrew Durham, Elen Jazrawi, Jo Ann Rhodes, Cara Williams, Ian Kilty, Peter Barnes, K. Fan Chung, Ian Adcock
European Respiratory Journal 2014 44: P3332; DOI:
Andrew Durham
1National Heart and Lung Institute, Imperial College London, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elen Jazrawi
1National Heart and Lung Institute, Imperial College London, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jo Ann Rhodes
1National Heart and Lung Institute, Imperial College London, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cara Williams
2Pfizer Inc, Pfizer Inc, Cambridge, MA,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian Kilty
2Pfizer Inc, Pfizer Inc, Cambridge, MA,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Barnes
1National Heart and Lung Institute, Imperial College London, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K. Fan Chung
1National Heart and Lung Institute, Imperial College London, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian Adcock
1National Heart and Lung Institute, Imperial College London, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

Sulforaphane (SFN) is a naturally occurring compound, found in cruciferous vegetables. SFN is a potent activator of the endogenous anti-oxidant transcription factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2). Due to its anti-oxidant and anti-inflammatory properties SFN has been identified as a potential treatment for a number of diseases including chronic obstructive pulmonary (COPD). We confirmed that SFN activates of the Nrf2 pathway and induces the expression of haemoxygenase (HO)-1 and NAD(P)H:Quinone Oxireductase (NQO)-1. SFN suppressed interleukin (IL)-1b-induced and IL-1b plus oxidative stress (hydrogen peroxide, H2O2)-induced CXCL8 expression in a concentration-dependent manner in human bronchial epithelial and monocyte cell lines. Nrf2 siRNA significantly reduced the ability of SFN to enhance Nrf2-mediated induction of HO-1 and NQO-1 without any effect on the ability of SFN to suppress IL-1b- and IL-1b+H2O2-induced CXCL8 expression in these cells. Our results suggest that the anti-inflammatory effects of SFN occur independently of Nrf2 in human airway epithelial cells and macrophages.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure legend. Nrf2 knockdown using siRNA abrogates the ability of sulpforophane to induce Nrf2 activation (A & B) and that of the downstream target NQO-1 (c & d) in BEAS-2B cells. Nrf2 knockdown does not have a significant effect on the ability of sulforophane to suppress IL-1b-induced CXCL8 release in BEAS-2B or U937 cells (e & f).

  • Inflammation
  • COPD - management
  • © 2014 ERS
Previous
Back to top
Vol 44 Issue Suppl 58 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The anti-inflammatory effects of sulforaphane are not mediated by the Nrf2 pathway
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The anti-inflammatory effects of sulforaphane are not mediated by the Nrf2 pathway
Andrew Durham, Elen Jazrawi, Jo Ann Rhodes, Cara Williams, Ian Kilty, Peter Barnes, K. Fan Chung, Ian Adcock
European Respiratory Journal Sep 2014, 44 (Suppl 58) P3332;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
The anti-inflammatory effects of sulforaphane are not mediated by the Nrf2 pathway
Andrew Durham, Elen Jazrawi, Jo Ann Rhodes, Cara Williams, Ian Kilty, Peter Barnes, K. Fan Chung, Ian Adcock
European Respiratory Journal Sep 2014, 44 (Suppl 58) P3332;
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Figures & Data
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Pharmacological characterization of the anti-oxidant activity of N-acetylcysteine in an ex vivo model of COPD exacerbation
  • TNFAIP3 (A20) expression is elevated in the sputum of severe asthmatics
  • Neurokinin-1 receptor antagonism for the treatment of cough in lung cancer
Show more 5.1 Airway Pharmacology and Treatment

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society